BRCA Tests Market Regulatory, Reimbursement and Forecasts to 2033
January 09, 2024 11:03 ET
|
Research and Markets
Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "BRCA Tests Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering....
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2023 08:30 ET
|
Imunon, Inc.
Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE...
Ovarian Cancer Drugs Market Size Worth USD 5.35 Billion in 2032 | Emergen Research
November 28, 2023 11:00 ET
|
Emergen Research
Vancouver, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The global ovarian cancer drugs market is set to experience substantial expansion, reaching a size of USD 2.40 Billion in 2022 and projecting an...
Monoclonal Antibodies Market Size Worth USD 572.62 Billion in 2032 | Emergen Research
November 28, 2023 08:17 ET
|
Emergen Research
Vancouver, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The global monoclonal antibodies market size was USD 204.42 billion in 2022 and is expected to register a revenue CAGR of 10.8% during the forecast...
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
November 27, 2023 07:00 ET
|
Genelux Corporation
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms
November 20, 2023 10:00 ET
|
Medicovestor Inc
Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
November 15, 2023 07:30 ET
|
AIM ImmunoTech Inc.
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will...
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
November 08, 2023 08:45 ET
|
AIM ImmunoTech Inc.
Data presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over...
Mendus presenterar uppdaterad data från ALISON-studien med vididencel i äggstockscancer vid SITC 2023
November 06, 2023 02:00 ET
|
Mendus AB
Pressmeddelande Stockholm, 6 november 2023 Mendus AB (“Mendus” publ; IMMU. ST), ett biofarmabolag med fokus på immunterapier riktade mot tumöråterfall, meddelade idag publiceringen av uppdaterade...
Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023
November 06, 2023 02:00 ET
|
Mendus AB
Press Release Stockholm, Sweden, November 6, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence,...